Skip to main
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Erasca Inc's pipeline demonstrates promising advancements in precision oncology, particularly with ERAS-0015 showing potential for best-in-class positioning due to early clinical activity and favorable pharmacokinetics. The company's dual approach of degrading RAS and inhibiting KRAS may significantly enhance the likelihood of establishing a robust portfolio that addresses challenges in historically resistant cancer types, thus increasing the probability of success to 25%. Furthermore, the anticipation surrounding upcoming clinical data disclosures in 2025 contributes to a positive outlook for Erasca's stock, as the company continues to differentiate itself within a competitive landscape.

Bears say

Erasca Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to inherent risks associated with its research and development pipeline. The company's leading candidate, Naporafenib, could encounter dose-limiting toxicity, which limits both therapeutic exposure and treatment durability, while historical failures of pan-RAS inhibitors highlight the difficulties in achieving sustained efficacy. Additionally, a notable percentage of tumors in Erasca's target indications are fundamentally non-RAS-dependent, indicating that the company's therapies may have an upper limit on their effectiveness, further complicating their competitive positioning in the oncology market.

Erasca Inc (ERAS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 9 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.